Epidemiology of atrial fibrillation: European perspective

By M. Zoni-Berisso, F. Lercari, T. Carazza, S. Domenicucci. Clinical Epidemiology, 2014

1,129 citations recorded by the source corpus.

In the last 20 years, atrial fibrillation (AF) has become one of the most important public health problems and a significant cause of increasing health care costs in western countries. The prevalence of AF is increasing due to our greater ability to treat chronic cardiac and noncardiac diseases, and the improved ability to suspect and diagnose AF. At the present time, the prevalence of AF (2%) is double that reported in the last decade. The prevalence of AF varies with age and sex. AF is present in 0.12%–0.16% of those younger than 49 years, in 3.7%–4.2% of those aged 60–70 years, and in 10%–17% of those aged 80 years or older. In addition, it occurs more frequently in males, with a male to female ratio of 1.2:1. The incidence of AF ranges between 0.21 and 0.41 per 1,000 person/years. Permanent AF occurs in approximately 50% of patients, and paroxysmal and persistent AF in 25% each. AF is frequently associated with cardiac disease and comorbidities. The most common concomitant diseases are coronary artery disease, valvular heart disease, and cardiomyopathy. The most common comorbidities are hypertension, diabetes, heart failure, chronic obstructive pulmonary disease, renal failure, stroke, and cognitive disturbance. Paroxysmal AF occurs in younger patients and with a reduced burden of both cardiac disease and comorbidities. Generally, the history of AF is long, burdened by frequent recurrences, and associated with symptoms (in two thirds of patients). Patients with AF have a five-fold and two-fold higher risk of stroke and death, respectively. We estimate that the number of patients with AF in 2030 in Europe will be 14–17 million and the number of new cases of AF per year at 120,000–215,000. Given that AF is associated with significant morbidity and mortality, this increasing number of individuals with AF will have major public health implications.

Subfields: Cardiology and Cardiovascular Medicine

View Paper: https://www.semanticscholar.org/paper/741a1c8ef74b949ec38ce452a7f73d0b6bc6000a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

Citations in the corpus

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. (2016, neutral): “By 2030, 14–17 million AF patients are anticipated in the European Union, with 120 000–215 000 newly diagnosed patients per year.(2,6,7) Estimates suggest an AF prevalence of approximately 3% in adults aged 20 years or older,(8,9) with greater prevalence in older persons(1) and in patients with cond”
Automated Atrial Fibrillation Detection using a Hybrid CNN-LSTM Network on Imbalanced ECG Datasets (2021, background): “It is the most common arrhythmia in clinical practice, which justifies the fact that many countries, especially these of the western world, allocate high budgets for handling it [25].”
Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge (2020, background): “The prevalence of AF is very low among young individuals (<1% in people aged< 40 years) but increases with age, reaching between 10% and 17% in those aged> 80 years.(9) With the worldwide aging of the population, an AF epidemic is expected within the next years.”
Partial Policy-Based Reinforcement Learning for Anatomical Landmark Localization in 3D Medical Images (2018, background): “potentially responsible for inducing stroke-risk in non-valvular atrial fibrillation [37].”